Next-Generation Synthetic pDNA Vaccines against SARS-CoV-2 Variants

A novel, self-amplifying pDNA vaccine platform that induces protective humoral and cellular responses against multiple SARS-CoV-2 variants, enhancing vaccine efficacy and providing a robust defense against emerging strains.

The original patent disclosed a synthetic pDNA vaccine against COVID-19, but its limitations in addressing multiple variants and enhancing vaccine efficacy are overcome by the present inventive concept, which leverages self-amplifying RNA molecules and machine learning algorithms to optimize polynucleotide sequences.

The next-generation pDNA vaccine platform comprises a polynucleotide sequence at least 95% identical to SEQ ID NO: 1, self-amplifying RNA molecules, and optional microneedle-based delivery systems. Machine learning algorithms are used to identify optimal polynucleotide sequences, ensuring enhanced vaccine efficacy against multiple SARS-CoV-2 variants. The platform also includes wearable devices and cloud-based databases for monitoring and predicting vaccine efficacy.

The combination of self-amplifying RNA molecules, machine learning algorithms, and microneedle-based delivery systems in a single pDNA vaccine platform constitutes a novel and non-obvious improvement over the original patent, providing a paradigm shift in vaccine development against emerging infectious diseases.

Alternative embodiments may include using different machine learning algorithms, incorporating additional adjuvants or immunomodulators, or utilizing various delivery systems, such as nanoparticles or electroporation. Variations may also include targeting different infectious diseases or using the platform for cancer immunotherapy.

The next-generation pDNA vaccine platform has significant commercial potential in the global vaccine market, particularly in the context of emerging infectious diseases. Target industries include pharmaceutical companies, biotechnology firms, and government agencies focused on public health and pandemic preparedness.